CellaVision ABCVLLY +12.06%69 Return-on-Tangible-Equity is 24.47% as of Mar. 2026, which is 49% below its 10-year median of 47.82. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 760 Medical Devices & Instruments companies, CellaVision AB ranks better than 90.79% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. CellaVision AB's annualized net income for the quarter that ended in Mar. 2026 was $9.66 Mil. CellaVision AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $39.48 Mil. Therefore, CellaVision AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 24.47%.
The historical rank and industry rank for CellaVision AB's Return-on-Tangible-Equity or its related term are showing as below:
CVLLY'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 36.74 Med: 47.82 Max: 100.86
Current: 38.93
During the past 13 years, CellaVision AB's highest Return-on-Tangible-Equity was 100.86%. The lowest was 36.74%. And the median was 47.82%.
CVLLY's Return-on-Tangible-Equity is ranked better than 90.79% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.115
vs CVLLY: 38.93
CellaVision AB (OTCPK:CVLLY) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
CellaVision AB Return-on-Tangible-Equity Related Terms
CellaVision AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVLLY vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, CellaVision AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 24.47% mean?
CellaVision AB (CVLLY) has a Return-on-Tangible-Equity of 24.47% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CellaVision AB and its competitors. This is 49% below median its historical median of 47.82. Over the past decade, CellaVision AB's Return-on-Tangible-Equity has ranged from 36.74 to 100.86. According to the industry distribution chart, CellaVision AB ranks #70 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 9.2%.
Is CellaVision AB's Return-on-Tangible-Equity too high?
CellaVision AB's current Return-on-Tangible-Equity of 24.47% is 49% below median its 10-year median of 47.82. Over the past 10 years, this metric has ranged from a low of 36.74 to a high of 100.86. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.12. CellaVision AB's value of 24.47% is 494.7% above this industry median. Based on the distribution chart, CellaVision AB ranks #70 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #70 out of 760 companies for Return-on-Tangible-Equity. This places CellaVision AB in the top 9% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.12. CellaVision AB's value of 24.47% is 494.7% above this benchmark. Historically, CellaVision AB's own Return-on-Tangible-Equity has ranged from 36.74 to 100.86 over the past decade. While the company's 10-year median is 47.82 vs. the industry median of 4.12, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.12, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Return-on-Tangible-Equity of 24.47% is 494.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Return-on-Tangible-Equity is 24.47%, which is 49% below median its own 10-year median of 47.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Return-on-Tangible-Equity is 24.47%, which is 49% below median its 10-year median of 47.82 and 494.7% above the Medical Devices & Instruments industry median of 4.12. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Return-on-Tangible-Equity is 24.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
Return-on-Tangible-Equity: 24.47% (49% below median its 10-year median of 47.82)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 494.7% above the Medical Devices & Instruments median (#70 of 760)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
